Drug Profile
Research programme: small molecule-based epilepsy therapeutics - Bicoll GmbH/InteRNA Technologies
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bicoll GmbH; InteRNA Technologies
- Class Small molecules
- Mechanism of Action MicroRNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Epilepsy in European Union
- 18 Sep 2013 Early research in Epilepsy in European Union (unspecified route)